Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond

DOI PDF PDF 4 Citations
  • Maria E Cabanillas
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • Mabel Ryder
    Department of Endocrinology and Medical Oncology, Mayo Clinic, Rochester, Minnesota
  • Camilo Jimenez
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas

Description

<jats:title>Abstract</jats:title><jats:p>The treatment of advanced thyroid cancer has undergone rapid evolution in the last decade, with multiple kinase inhibitor drug approvals for each subtype of thyroid cancer and a number of other commercially available drugs that have been studied for this indication. Although most of the US Food and Drug Administration (FDA)–approved drugs are antiangiogenic multikinase inhibitors—vandetanib, cabozantinib, sorafenib, lenvatinib—there are two FDA indications that are mutation specific—dabrafenib/trametinib for BRAF-mutated anaplastic thyroid cancer and larotrectinib for NTRK-fusion thyroid cancer. Furthermore, other mutation-specific drugs, immunotherapies, and novel strategies for advanced thyroid cancer are under investigation. Understanding the molecular basis of thyroid cancer, the drugs of interest for treatment of advanced thyroid cancer, and how these drugs can be administered safely and in the appropriate clinical scenario are the topics of this review.</jats:p>

Journal

  • Endocrine Reviews

    Endocrine Reviews 40 (6), 1573-1604, 2019-07-19

    The Endocrine Society

Citations (4)*help

See more

Report a problem

Back to top